COMMUNIQUÉS West-GlobeNewswire

L’association RYBREVANT®▼ (amivantamab) plus chimiothérapie démontre un taux de réponse globale de 49 pour cent dans le cancer colorectal métastatique

16/09/2024 - 16:11

La durée médiane de la réponse atteint 7,4 mois avec le traitement combiné chez les patients atteints d’une forme agressive de la maladie 1 De nouveaux résultats démontrent l’efficacité de l’amivantamab au-delà du [...]

ARC Fertility Sponsors Purchaser Business Group on Health 2024 Maternal Health and Birth Equity Summit

16/09/2024 - 16:02

CUPERTINO, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ARC Fertility (ARC), a highly experienced national provider of innovative fertility and family-forming benefits for employers and their employees, is pleased to [...]

RYBREVANT®▼ (amivantamab) associé à une chimiothérapie montre une tendance de survie globale positive par rapport à la chimiothérapie chez les patients atteints d'un cancer du poumon muté par EGFR préalablement traité

16/09/2024 - 16:00

Les résultats suite à la progression ont mis en évidence une amélioration significative et durable pour l'amivantamab plus chimiothérapie par rapport à la chimiothérapie seule 1 BEERSE, BELGIQUE, 16 sept. 2024 (GLOBE [...]

WellRithms Featured for Fourth Consecutive Year on Portland Business Journal List of Fastest-Growing Private Companies

16/09/2024 - 16:00

PORTLAND, Ore., Sept. 16, 2024 (GLOBE NEWSWIRE) -- WellRithms , the industry leading payment integrity firm, announces the Company’s fourth consecutive year of recognition from the Portland Business Journal as one of [...]

Thought Leadership & Innovation Foundation Announces Gala to Initiate Development of Patient Portal for Age-Related Macular Degeneration

16/09/2024 - 16:00

Howard Fine, MD Delivers Keynote MCLEAN, Va., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Thought Leadership & Innovation Foundation (TLI) , a not-for-profit organization that works at the nexus of science, technology and [...]

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

16/09/2024 - 15:31

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is [...]

Novo Nordisk A/S - share repurchase programme

16/09/2024 - 15:15

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]

Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy

16/09/2024 - 15:00

Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide therapy Equillium targeting initiation of Phase 1 study investigating EQ302 in 2H 2025 [...]

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

16/09/2024 - 15:00

GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]

London Man Grateful to Doctors Who Treated Rare Flesh-Eating Disease, Pledges $25,000

16/09/2024 - 15:00

LONDON, Ontario, Sept. 16, 2024 (GLOBE NEWSWIRE) -- While on vacation in Napa Valley last year, Colleen DeJager’s world imploded when she received a startling call from back home—her husband Rick was admitted to London [...]

T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

16/09/2024 - 15:00

Expands available market to include over 200 children’s hospitals in the United States LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid [...]

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

16/09/2024 - 14:53

Strengthens Rare Disease segment as largest driver of future growth , adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth [...]

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

16/09/2024 - 14:45

Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx ® (cabozantinib) versus placebo in advanced pancreatic and extra-pancreatic [...]

Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées

16/09/2024 - 14:45

Les données ont démontré une réduction significative, tant sur le plan statistique que sur le plan clinique, du risque de progression de la maladie ou de décès avec Cabometyx ® (cabozantinib) par rapport au placebo dans [...]

NeuroStar® Releases Software Upgrades to Elevate Patient Care

16/09/2024 - 14:32

Upgrades improve communication, streamline data management, and strengthen security MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, [...]

Merit Medical’s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients

16/09/2024 - 14:30

In the US pivotal trial, WRAPSODY achieved 89.8% target lesion primary patency at 6 months SOUTH JORDAN, Utah, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare [...]

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

16/09/2024 - 14:30

SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical [...]

BAMF Health Announces Strategic Clinical Trials Partnership with Adaptive Research

16/09/2024 - 14:30

Partnership increases physician and patient participation in clinical trials GRAND RAPIDS, Mich. and SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BAMF Health, a world leader in molecular imaging and Theranostics [...]

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

16/09/2024 - 14:30

Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for [...]